Funding Opportunity RFA-DK-19-008 from the NIH Guide for Grants and Contracts. The prevalence of obesity is increasing in people with HIV (PWH), contributing to multiple complications associated with this condition. There is mounting evidence that there are unique mechanisms contributing to the development of obesity in PWH versus people without HIV. Furthermore, the biology of the adipocytes might be altered in overweight or obese PWH versus overweight or obese people without HIV. This FOA seeks applications to elucidate the underlying mechanisms of how HIV and antiretroviral drugs used for therapy or pre-exposure prophylaxis contribute to the development of obesity and alter adipocyte and adipose tissue function as well as the effects of these processes on metabolic and physiological processes within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Notice NOT-DA-19-042 from the NIH Guide for Grants and Contracts

Notice NOT-CA-19-058 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-NS-19-037 from the NIH Guide for Grants and Contracts. Reissue of RFA-NS-18-032. The purpose of the NINDS Research Program Award (RPA) is to provide longer-term support and increased flexibility to Program Directors (PDs) /Principal Investigators (PIs) whose records of research achievement demonstrate their ability to make major contributions to neuroscience. RPAs will support the overall research programs of NINDS-funded investigators for up to 8 years, at a level commensurate with a PD/PI's recent NINDS support (Part 2, Section II) This greater funding stability will provide eligible investigators at nearly all career stages increased freedom and flexibility, allowing them to be more adventurous in their research, take greater risks, embark upon research that breaks new ground, undertake research projects that require a longer timeframe, and/or extend previous discoveries in new directions. Research supported through the RPA must be within the scope of the NINDS mission (http://www.ninds.nih.gov/about_ninds/mission.htm). Research activities outside of the NINDS mission, or traditionally supported by another NIH Institute or Center will not be considered through this program. Other anticipated benefits of the RPA include: A more stable funding environment, facilitating the pursuit of longer-term research goals; Flexible funding, enabling investigators to pursue research opportunities as they arise, not tied to specific aims; Reduced time spent writing grant applications and managing multiple grant awards, thereby allowing investigators to spend more time conducting and overseeing research; and More time for PDs/PIsto mentor junior scientists. Eligibility to apply through this FOA is limited to investigators who currently have at least one active NINDS R01 or R01 equivalent grant (defined here as R00, R01, R37, R56, DP1 or DP2 awards), and who have had an active R01 equivalent grant from NINDS in each of the past 5 years, with no more than one of those years in a no cost extension.

Funding Opportunity PAR-19-289 from the NIH Guide for Grants and Contracts. The overall goal of this Funding Opportunity Announcement (FOA) is to identify, in animals, in vivo neurophysiological and behavioral measures for use as assays in the early screening phase of treatment development. The FOA will support efforts to optimize and evaluate measures of neurophysiological and behavioral processes that may serve as surrogate markers of neural processes of clinical interest based on available knowledge of the neurobiology of mental illnesses. The screening assays thus developed from this FOA are expected to build upon systems neurobiology and clinical neuroscience to enhance the scientific value of preclinical animal data contributing to a therapeutic development pipeline by assessing the impact of therapeutic targets and treatment candidates on neurobiological mechanisms of clinical relevance to mental illnesses.

Salary in the region of £36,737- £44,451 (dependent on experience) plus excellent benefits: Wellcome Sanger Institute: Job Reference 83500 Senior Bioinformatician - Wormbase Salary in the region of £36,737- £44,451 (dependent on experience) plus excellent benefit Hinxton, Cambridgeshire, England

Notice NOT-GM-19-044 from the NIH Guide for Grants and Contracts

Notice NOT-GM-19-042 from the NIH Guide for Grants and Contracts

Notice NOT-GM-19-043 from the NIH Guide for Grants and Contracts

Competitive Salary: EMBL: Operations Bioinformatician - European Genome-phenome Archive Cambridge, Cambridgeshire, England

Skills in bioinformatics, gene expression analysis, metabolic profiling, or amino acid analysis. Practical experience of next-generation sequencing data... $62,236 a year
From Oak Ridge Associated Universities - Fri, 24 May 2019 20:18:05 GMT - View all Madison, WI jobs

Competitive Salary: EMBL: Software engineer Location: EMBL Cambridge, Cambridgeshire, England

£40000 - £60000 per annum: CK Group: Jade Stirk at CK Science is currently recruiting for a Bioinformatics Scientist to join a growing spin out company from the University of Cambridge specialising... Cambridge

Up to £450 pd LTD: CK Group: Jenni at CK Group is recruiting for a Business Analyst to join a company in the pharmaceutical industry at their site based in Melbourn, Royston... Royston

Funding Opportunity RFA-HG-19-013 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to participate in the Electronic Medical Records and Genomics (eMERGE) Genomic Risk Assessment and Management Network. This network will continue to use biorepositories linked with electronic medical records (EMRs) for genomic research by developing, evaluating, and disseminating genomic risk assessment and management tools for clinical use. Applicants to this FOA are expected to recruit a minimum of 35% of patients who come from racial or ethnic minority populations, underserved populations, or populations who experience poorer medical outcomes. In contrast, applicants to the companion RFA-HG-19-014 are expected to recruit a minimum of 75% of such patients.

Funding Opportunity RFA-HG-19-014 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to participate in the Electronic Medical Records and Genomics (eMERGE) Genomic Risk Assessment and Management Network. This network will continue to use biorepositories linked with electronic medical records (EMRs) for genomic research by developing, evaluating, and disseminating genomic risk assessment and management tools for clinical use. Applicants to this FOA are expected to recruit a minimum of 75% of patients who come from racial or ethnic minority populations, underserved populations, or populations who experience poorer medical outcomes. In contrast, applicants to the companion RFA-HG-19-013 are expected to recruit a minimum of 35% of such patients.

Funding Opportunity RFA-HG-19-015 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to continue genomic implementation research in the Electronic Medical Records and Genomics (eMERGE) Network by providing support for a Coordinating Center (CC) to provide centralized support, infrastructure, coordination, and data analysis for the program.

Competitive Salary: EMBL: Full Stack Developer Location: E Cambridge, Cambridgeshire, England

Funding Opportunity RFA-AG-20-025 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to support research focused on understanding the role of senescence in brain aging and in Alzheimer's disease (AD). This FOA encourages research projects addressing critical knowledge gaps in our understanding of the neurobiology of senescence through cutting-edge techniques, cross-disciplinary collaborations, and/or conceptual innovation, leveraging what is known about senescence in peripheral tissues to learn more about brain aging. Developing a clear understanding of the mechanisms driving aging processes in the brain, including senescence, is essential for combating age-related neurodegenerative diseases.

Funding Opportunity PAR-19-288 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to continue the operations of the NIA Genome Center for Alzheimer's Disease (GCAD) to facilitate and support the Alzheimer's Disease Sequencing Project (ADSP) activities. GCAD will serve as the focal point for all phases of ADSP quality control checking, data harmonization, and meta-analysis. The FOA is intended to support a major component of the full range of analysis for the ADSP. The spectrum of the Center's activities comprises a multidisciplinary attack on Alzheimer's Disease (AD) and AD Related Dementias (ADRD) in keeping with NIA's programmatic needs. The Center will serve as a national resource for the specific purpose of identifying potential avenues for therapeutic approaches and prevention of the disease.